Abstract
From 1519 newly diagnosed HIV individuals seen in Madrid between the years 2000 and 2008, 65 (4.3%) were HBsAg(+). Two HIV/HBV-coinfected patients showed the lamivudine resistance mutation M204V in HBV while no drug resistance mutations were recognized in HIV. None of them admitted prior exposure to antiretroviral drugs. Thus, HIV/HBV-coinfected patients might benefit from baseline drug resistance testing for both HIV and HBV to optimize the selection of anti-HBV active antiviral therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / therapeutic use*
-
Drug Resistance, Viral / genetics*
-
Female
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV Infections / virology
-
Hepatitis B Surface Antigens / blood
-
Hepatitis B virus / genetics*
-
Hepatitis B, Chronic / complications*
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / transmission*
-
Hepatitis B, Chronic / virology
-
Humans
-
Lamivudine / therapeutic use*
-
Male
-
Mutation
Substances
-
Anti-HIV Agents
-
Hepatitis B Surface Antigens
-
Lamivudine